BTK Inhibitor: ASH Congress Data on Zanubrutinib’s del(17p) CLL Performance – Insights from the SEQUOIA zanubrutinib study 

Treatment strategies for chronic lymphocytic leukemia (CLL) continue to evolve in the frontline setting. Data presented at the American Society of Hematology (ASH) Congress highlighted long-term findings from the SEQUOIA study evaluating zanubrutinib, a next-generation Bruton tyrosine kinase (BTK) inhibitor, including outcomes in patients with del(17p), a genetic abnormality associated with poor prognosis following conventional chemoimmunotherapy. 

Overview of the SEQUOIA Study 

The SEQUOIA zanubrutinib study is a Phase III clinical trial evaluating zanubrutinib in treatment-naïve patients with CLL or small lymphocytic lymphoma (SLL). The study compared continuous zanubrutinib therapy with the standard chemoimmunotherapy regimen bendamustine plus rituximab (BR) in patients without del(17p). 

In a separate cohort (Arm C), patients with del(17p) received continuous zanubrutinib. This design allowed for the evaluation of clinical outcomes both in the overall frontline population and specifically in a high-risk genetic subgroup. 

The primary objective of the study was to assess long-term efficacy and safety, including progression-free survival (PFS), time to next treatment, and tolerability. 

Long-Term Efficacy and Safety Outcomes 

With 6 years of follow-up, zanubrutinib demonstrated sustained improvement in progression-free survival compared with bendamustine plus rituximab in patients without del(17p). Fewer patients receiving zanubrutinib required subsequent therapy during the follow-up period. 

• Time to next treatment was prolonged in the zanubrutinib arm. The long-term safety profile remained consistent with earlier analyses, and no new safety signals were identified over extended follow-up. 
• Given that CLL is typically managed as a chronic condition, durability of response and long-term tolerability remain important considerations in treatment selection. 

How Zanubrutinib Performed in Patients with del(17p) 

In the del(17p) cohort of the SEQUOIA study, patients treated with continuous zanubrutinib demonstrated sustained progression-free survival over long-term follow-up. Survival outcomes were reported to be comparable to those observed in other SEQUOIA cohorts without the high-risk deletion. 

These results suggest that BTK inhibition may help address historical outcome differences associated with del(17p) in frontline CLL management. 

What ASH Data Mean for Clinical Practice 

These results suggest that BTK inhibition may help address historical outcome differences associated with del(17p) in frontline CLL management. 

1. Frontline BTK Inhibition Becomes More Attractive 

BTK inhibitors are increasingly incorporated into frontline treatment strategies for CLL. The long-term data from SEQUOIA provide additional evidence supporting the use of zanubrutinib as a frontline option, including in patients who may not be ideal candidates for intensive chemoimmunotherapy. 

2. Genetic Risk and Treatment Decision-Making 

Routine assessment for genetic abnormalities such as del(17p) remains important in guiding treatment decisions. The observed outcomes with zanubrutinib in this subgroup may inform therapeutic discussions in clinical practice. 

3. Long-Term Treatment Considerations 

Sustained efficacy and consistent safety over extended follow-up support consideration of BTK inhibition in long-term disease management strategies. 

Final Thoughts 

The long-term data from the SEQUOIA study presented at ASH provide updated clinical evidence regarding the use of zanubrutinib in treatment-naïve CLL, including patients with del(17p). The results demonstrate durable disease control and a consistent safety profile over extended follow-up. 

FAQs 

Q1. How does zanubrutinib work? 

A: Zanubrutinib is a next-generation Bruton tyrosine kinase (BTK) inhibitor designed to block a key pathway that helps CLL/SLL cancer cells survive and proliferate. 

Q2: What do SEQUOIA study results mean for frontline treatment of TN CLL/SLL? 

A: With 6 years of follow-up, zanubrutinib demonstrated sustained efficacy, durable progression-free survival, delayed need for subsequent therapy, and a manageable safety profile. These findings support zanubrutinib as an effective and tolerable frontline treatment option for patients with TN CLL/SLL, including those with high-risk features such as del(17p).